Bleakley Financial Group LLC Purchases 15,495 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Bleakley Financial Group LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 60.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 40,979 shares of the biopharmaceutical company's stock after acquiring an additional 15,495 shares during the period. Bleakley Financial Group LLC's holdings in Gilead Sciences were worth $4,592,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences in the first quarter valued at about $25,000. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences during the first quarter valued at approximately $29,000. Annis Gardner Whiting Capital Advisors LLC grew its stake in shares of Gilead Sciences by 158.8% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares during the period. Core Alternative Capital raised its holdings in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares in the last quarter. Finally, Lee Danner & Bass Inc. bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $41,000. Institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

GILD has been the topic of a number of analyst reports. Oppenheimer lowered their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Morgan Stanley increased their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $111.38.

Gilead Sciences Trading Up 0.7%

NASDAQ:GILD traded up $0.79 on Wednesday, hitting $109.85. 3,957,440 shares of the stock were exchanged, compared to its average volume of 7,682,451. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a 52 week low of $70.78 and a 52 week high of $119.96. The stock has a market capitalization of $136.65 billion, a price-to-earnings ratio of 23.13, a P/E/G ratio of 0.71 and a beta of 0.29. The company's 50-day moving average price is $108.37 and its 200 day moving average price is $104.94.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period in the prior year, the business posted ($1.32) earnings per share. Gilead Sciences's revenue was down .3% compared to the same quarter last year. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.88%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the sale, the chief financial officer directly owned 162,610 shares of the company's stock, valued at $18,054,588.30. The trade was a 1.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at $978,880.80. The trade was a 35.92% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,000 shares of company stock worth $7,844,775. Company insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.